Revolution Medicines focuses on developing targeted therapies for cancer treatment. The company is self-described as being 'on target' to outsmart cancer.

Revolution Medicines

Domain Not Resolving

HSTS

DNSSEC

Google Maps

Cloudflare CDN

Microsoft Exchange Online

DMARC

IPv6

Office 365 Mail

F45 Studio Owner

Jeremias Cardoso

Founder & CEO

Michael Glickman

Business Management

Peg Horn

Senior Vice President Investor Relations & Corporate Affairs

David Arrington

Jan Smith

Director, Non-Clinical Operations

Alex Nguyen

Director/ Head of Biology Research Operations

Alexander McNamara

Associate Director, Program Management, Program, Portfolio, and Alliance Management (PPAM)

Alive Xiao

Aman D.

Associate Director Clinical Operations

Ana M.

Barbara Weber

Liz McKee Anderson

Mark A. Goldsmith

Thilo Schroeder

Larry Lasky

Vincent A. Miller

Neil Exter

Founding President & Chief Executive Officer

Martin D. Burke

Founder & Scientific Advisory Board Chairman

Michael Flagella

Director, Head of Toxicology

Luan M. Wilfong

Chief Human Resources Officer

Alexis Borisy

Founding Investor and Board Member

Margaret Horn

Chief Operating Officer

Xiaolin Wang

SVP Clinical Development

Luan Wilfong

Silicon Valley Companies With More Than 100 Employees

Health Care Companies that Exited (Top 10K)

The Column Group Portfolio Companies

Medical Public Companies With More Than $10M in Revenue

Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.

REVOLUTION Medicines builds upon the vision of the company’s founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology.

REVOLUTION Medicines’ approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates.

Post-IPO Equity - Revolution Medicines

Boxer Capital

Series C - Revolution Medicines

Nextech Invest

Series B - Revolution Medicines

The Column Group

Third Rock Ventures

Series A - Revolution Medicines

Redwood City

California

United States

North America

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

Revolution Medicines presents initial data from RMC-9805 study

Needham Reiterates Buy on Revolution Medicine...

Revolution Medicines data validates RMC-6236's anti-tumor activity, says Wedbush

Revolution Medicines added to JPMorgan focus list due to NSCLC asset

Revolution Medicines participates in a conference call with JPMorgan

JPMorgan raises Revolution shares target on clinical updates

Positive Data in Pancreatic Cancer Pave Way for Pivotal Test of Revolution Medicines Drug

A RAS(ON) multi-selective inhibitor designed for the treatment of RAS-addicted cancers.

A RAS(ON) G12C-selective inhibitor targeting specific mutations in RAS-addicted cancers.

A RAS(ON) G12D-selective inhibitor aimed at addressing mutations in RAS-addicted cancers.

A platform enabling the creation of inhibitors that target the active state of RAS proteins, offering a novel approach to cancer treatment.

India

Asia

Philippines

Nigeria

Africa

Canada

HTML5

GoDaddy

F5 NGINX

DigiCert

Bootstrap

jQuery

Google Fonts

Google Analytics

Office 365

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 23, 2024 8:12 PM	0f9332f4
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 23, 2024 8:12 PM	7fc3aaa5
crunchbase trigger	general	Nov 22, 2024 7:44 AM	8947e2d9
crunchbase profile	general	Nov 23, 2024 4:10 AM	cdbadcfe
li profile	general
translate crunchbase fundingrounds	general	Nov 23, 2024 4:50 AM	586ce838
peers	general	Oct 23, 2024 8:12 PM	e0d0c00e
news basic	general	Oct 23, 2024 8:12 PM	585e7211
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:REVMED

Revolution Medicines

Last Close

56.78

22/11 21:00

Market Cap

7.01B

Beta: -

Volume Today

1.17M

Avg: -